|Bid||5.49 x 800|
|Ask||5.49 x 1400|
|Day's Range||5.39 - 5.90|
|52 Week Range||1.56 - 6.30|
|Beta (3Y Monthly)||3.01|
|PE Ratio (TTM)||5.64|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.75|
Passive investing in index funds can generate returns that roughly match the overall market. But you can significantly...
Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (ZIOP), today announced Heidi Hagen, an experienced and entrepreneurial biotechnology operations executive, has been appointed to the Company’s Board of Directors effective immediately.
Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (ZIOP) announced that the investigational new drug (IND) application submitted by the National Cancer Institute (NCI) has received clearance from the U.S. Food and Drug Administration (FDA) for a clinical trial in solid tumors to evaluate T-cell receptor (TCR) T-cell therapy utilizing Ziopharm’s Sleeping Beauty platform. “This study is the result of extensive work by Dr. Steven Rosenberg and his team at the NCI, including Dr. Drew Deniger, to harness our Sleeping Beauty non-viral gene transfer technology to express neoantigen-specific T-cell receptors (TCRs),” said Dr. Laurence Cooper, Chief Executive Officer of Ziopharm.
BOSTON, June 02, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (ZIOP), a clinical stage immuno-oncology company developing next-generation cell and gene therapies, today announced the presentation of new interim analyses of clinical data from two ongoing substudies in its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex (Ad+V), both as monotherapy and in combination with a PD-1 inhibitor, for the treatment of recurrent or progressive glioblastoma multiforme (rGBM) in adults, at the American Society for Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31 to June 4, 2019. “Profiling an expanded number of patients with rGBM shows that Controlled IL-12 engages patients’ immune systems which we previously showed was an indicator of improved overall survival,” said Laurence Cooper, M.D., Ph.D., CEO of Ziopharm.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 28) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Arrowhead ...
– Scope of license includes library of T-cell receptors (TCRs) against neoantigens in hotspots including mutated KRAS, p53 and EGFR for use with Sleeping Beauty platform – –.
BOSTON, May 23, 2019 -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), a clinical stage immuno-oncology company developing next generation cell and gene therapies, today announced that.
The Boston-based company said it had a loss of 8 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss ...
BOSTON, May 08, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (ZIOP), a clinical stage immuno-oncology company developing next generation cell and gene therapies, today announced its financial results for the first quarter ended March 31, 2019, and provided an update on the Company’s recent activities. All three of our novel immuno-oncology programs are expected to be in the clinic this year,” said Laurence Cooper, M.D., Ph.D., CEO of Ziopharm. “We are looking forward to treating patients with solid tumors mid-year with the first non-viral, neoantigen-specific TCR-T cell therapy at the National Cancer Institute (NCI).
NEW YORK, NY / ACCESSWIRE / May 8, 2019 / ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 4:30 PM Eastern ...
BOSTON, May 01, 2019 -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast on Wednesday, May 8, at 4:30 p.m. ET to.
The big shareholder groups in ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companie...
Ziopharm said the FDA granted Fast Track designation for its Ad-RTS-hIL-12 plus veledimex, which is being evaluated for the treatment of recurrent or progressive glioblastoma multiforme, or rGBM in adults. The Fast Track designation facilitates the development and expediting of the review of drugs to treat serious conditions.
“Recurrent glioblastoma multiforme is an aggressive and life-threatening cancer of the central nervous system for which there are few treatment options and no cure,” said Laurence Cooper, M.D., Ph.D., CEO of Ziopharm.
- Phase 1 Trial of Sleeping Beauty-TCR-T cell therapy for patients with solid tumors to begin at National Cancer Institute in mid-2019 –- Third-generation Sleeping Beauty.
BOSTON, Feb. 25, 2019 -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast slide presentation on Tuesday, March 5,.
BOSTON, Feb. 21, 2019 -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that Chief Executive Officer Laurence Cooper, M.D., Ph.D, is scheduled to present and participate.
NEW YORK, Feb. 14, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Laurence James Cooper has been the CEORead More...
Ziopharm Oncology, Inc. (ZIOP) today announced that it rapidly completed enrollment and treated a total of 36 patients in less than six months in a substudy (Clinicaltrials.gov NCT03679754) to expand a Phase 1 trial evaluating its Controlled IL-12 platform as a monotherapy for the treatment of recurrent glioblastoma (rGBM). The trial was over enrolled with eleven more patients than the target goal of 25, which the Company attributes to enthusiasm stemming from the trial’s encouraging survival and tumor biopsy data. Ziopharm is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as a drug to control the production of interleukin 12 (IL-12).
The market for cell therapies of all kinds is exploding in size. Orgenesis Inc (ORGS) is making a name for itself as a top-notch provider of manufacturing to cell therapy drug developers. The company's revenue is growing consistently, and they recently achieved a key milestone under a 2018 investment agreement from a leading healthcare investment groups in the U.S., Great Point Partners.